FDA Inspection 1223799 — Bioreliance Ltd.
The FDA completed an inspection of Bioreliance Ltd. on November 7, 2023 in Stirling, Scotland. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 7, 2023
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Stirling, Scotland (United Kingdom)